Comparison of Helicobacter pylori Eradication Rates of 2-Week Levofloxacin-Containing Triple Therapy, Levofloxacin-Containing Bismuth Quadruple Therapy, and Standard Bismuth Quadruple Therapy as a First-Line Regimen

被引:11
|
作者
Aksoy, Evrim Kahramanoglu [1 ]
Sapmaz, Ferdane Pirincci [1 ]
Goktas, Zeynep [2 ]
Uzman, Metin [1 ]
Nazligul, Yasar [1 ]
机构
[1] Hacettepe Univ, Kecloren Training & Res Hosp, Dept Gastroenterol, Sanatoryum Caddesi Ardahan Sokak D 25, TR-06280 Ankara, Turkey
[2] Hacettepe Univ, Kecloren Training & Res Hosp, Dept Nutr & Dietet, Fac Hlth Sci, Ankara, Turkey
关键词
Helicobacter pylori infection; Bismuth-containing quadruple therapy; Levofloxacin-containing triple therapy; Eradication rate; RESCUE REGIMENS; EFFICACY; CLARITHROMYCIN; RESISTANCE; METAANALYSIS; INFECTION;
D O I
10.1159/000484930
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: The aim of this study was to compare the efficacy and safety of 2-week levofloxacin-containing triple therapy, levofloxacin-containing bismuth quadruple therapy, and standard bismuth-containing quadruple therapy as a firstline regimen for the eradication of Helicobacter pylori. Methods: A total of 329 patients with H. pylori infection were randomly divided into 3 groups to receive one of the following regimens: (a) levofloxacin-containing bismuth quadruple therapy RBAL (rabeprazole 20 mg, b.i.d., bismuth subsalicylate 562 mg, b.i.d., amoxicillin 1 g, b.i.d, levofloxacin 500 mg, once daily), (b) standard bismuth quadruple therapy, RBMT (rabeprazole 20 mg, b.i.d, subsalicylate 562 mg, b.i.d., metronidazole 500 mg, t.i.d, tetracycline 500 mg, q.i.d), or (c) levo-floxacin-containing triple therapy, RAL (rabeprazole 20 mg, b.i.d., amoxicillin 1 g, b.i.d, levofloxacin 500 mg, once daily). The primary outcome was the eradication rate in the intention-to-treat (ITT) and per protocol (PP) analysis. Results: The eradication rates of the above 3 groups using ITT analysis were RBAL 83.8%, RBMT 88.3%, and RAL 74.8% compared with 91.2, 92.5, and 79.2%, respectively, using PP analysis. The eradication rate using RBMT was significantly higher than that of RAL (p = 0.029 in ITT analysis and p = 0.017 in PP analysis). Several side effects occurred in 156 patients (54.1%) in the RBAL group, 215 (52.3%) in the RBMT group, and 56 (26.2%) in the RAL group (p > 0.05, RBAL vs. RBMT; p < 0.001, RBMT vs. RAL; p < 0.001, RBAL vs. RAL). Conclusion: All bismuth-containing quadruple therapies had acceptable eradication rates, but levofloxacin-containing triple therapy was not as good as quadruple therapies. Hence, quadruple therapies should be considered the preferred first-line therapy for H. pylori infections. (C) 2017 The Author(s) Published by S. Karger AG, Basel
引用
收藏
页码:523 / 529
页数:7
相关论文
共 50 条
  • [1] Efficacy of concomitant non-bismuth quadruple therapy or levofloxacin-containing triple therapy after bismuth containing quadruple therapy failure in clarithromycin-resistant Helicobacter Pylori
    Kim, S.
    Choi, C.
    Kang, D.
    Nam, H.
    Ryu, D.
    [J]. HELICOBACTER, 2016, 21 : 143 - 144
  • [2] META-ANALYSIS OF LEVOFLOXACIN-CONTAINING TRIPLE THERAPY VERSUS BISMUTH-CONTAINING QUADRUPLE THERAPY AS SECOND-LINE TREATMENT IN THE ERADICATION OF HELICOBACTER PYLORI
    Marin, A. C.
    McNicholl, A. G.
    Gisbert, J. P.
    [J]. HELICOBACTER, 2011, 16 : 132 - 132
  • [3] Levofloxacin-containing triple therapy versus bismuth-based quadruple therapy as regimens for second line anti- Helicobacter pylori
    Seyyedmajidi, Mohamadreza
    Abbasi, Laleh
    Seyedmajidi, Seyedali
    Hosseini, Seyed Ashkan
    Ahmadi, Anahita
    Hajiebrahimi, Shahin
    Vafaeimanesh, Jamshid
    [J]. CASPIAN JOURNAL OF INTERNAL MEDICINE, 2019, 10 (02) : 211 - 216
  • [4] LEVOFLOXACIN-CONTAINING QUADRUPLE CONCOMITANT THERAPY FOR ERADICATION OF H PYLORI INFECTION
    Gravina, A. G.
    Miranda, A.
    Micera, F.
    Zagaria, R.
    Napoletano, D.
    Federico, A.
    Romano, M.
    [J]. DIGESTIVE AND LIVER DISEASE, 2011, 43 : S188 - S189
  • [5] Meta-Analysis of Levofloxacin-Containing Triple Therapy vs. Bismuth-Containing Quadruple Therapy as Second-Line Treatment in the Eradication of Helicobacter pylori
    Marin, Alicia C.
    McNicholl, Adrian G.
    Gisbert, Javier P.
    [J]. GASTROENTEROLOGY, 2011, 140 (05) : S880 - S880
  • [6] Meta-Analysis of Levofloxacin-Containing Triple Therapy vs. Bismuth-Containing Quadruple Therapy as Second-Line Treatment in the Eradication of Helicobacter pylori
    Marin, Alicia C.
    McNicholl, Adrian G.
    Gisbert, Javier P.
    [J]. GASTROENTEROLOGY, 2012, 142 (05) : S483 - S483
  • [7] Levofloxacin-containing Triple and Sequential Therapy or Standard Sequential Therapy as the First Line Treatment for Helicobacter pylori Eradication in China
    Qian, Juan
    Ye, Feng
    Zhang, Jun
    Yang, Yan-Mei
    Tu, Hui-Ming
    Jiang, Qi
    Shang, Li
    Pan, Xiao-Lin
    Shi, Rui-Hua
    Zhang, Guo-Xin
    [J]. HELICOBACTER, 2012, 17 (06) : 478 - 485
  • [8] COMPARISON OF CONCOMITANT QUADRUPLE THERAPY AND LEVOFLOXACIN-CONTAINING TRIPLE THERAPY FOR THE TREATMENT OF CLARITHROMYCIN-RESISTANT HELICOBACTER PYLORI INFECTION
    Kim, S.
    Choi, C.
    Kang, D.
    Kim, H.
    Park, S.
    Nam, H.
    Ryu, D.
    Kim, W.
    [J]. HELICOBACTER, 2015, 20 : 102 - 102
  • [9] The Eradication Efficacies of Hybrid Therapy As First-Line Regimen Plus Levofloxacin-Containing Triple Therapy As Second-Line Regimen for Helicobacter pylori Infection
    Song, Zhiqiang
    Zhou, Liya
    Zhang, Jianzhong
    He, Lihua
    [J]. GASTROENTEROLOGY, 2015, 148 (04) : S421 - S421
  • [10] Bismuth quadruple therapy versus levofloxacin triple therapy for first-line helicobacter pylori eradication treatment: multicenter study
    Tran Thi Khanh Tuong
    Huynh Quang Huy
    Tong Nguyen Diem Hong
    Nguyen Thi Anh Dao
    Ngo Thi Thanh Quyt
    [J]. MEDICAL SCIENCE, 2020, 24 (104) : 2245 - 2250